Ultragenyx Pharmaceutical Reports Q3 Net Loss Widening, Revenue Growth

Ultragenyx Pharmaceutical's Q3 net loss widened, while revenue increased. The company's therapies and clinical-stage pipeline consist of biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Ultragenyx has four approved products: Crysvita, Mepsevii, Dojolvi, and Evkeeza. Its clinical product candidates include DTX401, DTX301, and UX701, targeting glycogen storage disease type la, among other conditions.